A recent phase 2 study on local consolidative therapy (LCT) combined with systemic chemotherapy for patients with stage IV non-small cell lung cancer (NSCLC) with oligometastases showed promising results. The study involved 19 efficacy evaluable patients who received platinum-based chemotherapy and thoracic chemoradiotherapy, followed by LCT for distant disease. After a median follow-up of 42.1 months, the 2-year survival rate was 68.4%, with a median overall survival of 42.1 months. The response rate was 57.9%, with 57.9% of patients showing a partial response and 42.1% having stable disease. These findings suggest that aggressive LCT in combination with chemotherapy could be effective and well-tolerated in this patient population.
The trial’s results also pointed to the need for further studies to improve treatment outcomes. While the treatment was associated with manageable side effects such as decreased neutrophil and white blood cell counts, along with common radiotherapy-related issues like esophagitis and radiation dermatitis, there were no treatment-related deaths. The study authors suggest incorporating immune checkpoint inhibitors into future research to further enhance outcomes and explore optimal treatment administration for broader clinical application.
Reference: Fabbricatore R. Local Consolidative Therapy Combo May Extend Survival in Stage IV NSCLC. CancerNetwork. Published January 22, 2025. Accessed January 30, 2025. https://www.cancernetwork.com/view/local-consolidative-therapy-combo-may-extend-survival-in-stage-iv-nsclc
